The TTC Oncology Clinical Advisory Board

Dallas/Fort Worth Living Legend Chair of Cancer Research

Professor of Breast medical Oncology

Professor of Molecular and Cellular Oncology

Chief, Section of Basic Science Research and Pharmacology

Member of the National Academy of Sciences

Member of the National Academy of Medicine



Dr. V. Craig Jordan

OBE, Ph.D, DSc, FMedSci, FAACR

Dr. Jordan’s translational research over the past four decades established the standard of care for the endocrine treatment of breast cancer, chemoprevention of breast cancer and the first studies of the evolution of drug resistance to long-term anti-estrogen therapy. Dr. Jordan’s findings include application of the original SERM, the estrogen-blocking drug tamoxifen, to the treatment and prevention of breast cancer, and discovery that raloxifene prevents both osteoporosis and breast cancer. The two widely used drugs are among five SERMs approved by the FDA for a variety of indications and all five are connected to basic research in Dr Jordan’s laboratory.

Professor of Medicine and Pharmacology (Joint Appointment), Division of Hematology, Oncology and Transplantation

Director, Masonic Cancer Center (MCC)

Professor, Department of Pharmacology

Microbiology, Immunology and Cancer Biology (MICaB) Ph. D. Graduate Program

Medical Oncologist

Dr. Douglas Yee

Dr. Yee holds the John H. Kersey Chair in Cancer Research. He was previously co-leader of the Women’s Cancer Program. He was named Director of the Masonic Cancer Center, University of Minnesota 2007. Dr Yee received his MD in 1981 for the University of Chicago. He received his internal medicine training and was Chief Medical Resident at the University of North Carolina. His medical oncology training was done at the National Cancer Institute in Bethesda, Maryland. He held faculty positions at Georgetown University Medical Center and the University of Texas Health Science Center at San Antonio.

Professor of Medicine University of Chicago

Director, Medical Oncology Breast Program University of Chicago

Medical Oncology Director, Gynecologic Oncology

Dr. Gini Fleming

Dr. Fleming is an expert in breast and gynecological cancers. Her recent research examines novel therapeutics in breast, ovarian and endometrial cancers. Dr Fleming has authored and co-authored more than 100 articles for a variety of medical journals, in addition to a number of textbook chapters. She serves on the editorial board for Gynecologic Oncology.

©2018 by TTC Oncology.